MS & PHD STUDENTS

Brendan Frett, PhD

Degree: 
PhD
Program: 
Pharmaceutical Sciences
Track: 
Drug Discovery and Development
Dissertation Title: 
"Discovery and Development of Novel RET Inhibitors for the Treatment of Pervasive Malignancies"

Alumnus
Year Graduated: 2014
Career Type: Academia
Post Doctoral Research Associate, The University of Arizona

Honors & Achievements
1. Mary E. Caldwell Memorial Scholarship, 2012-13.
2. NIH Training Grant Research Fellowship-Biological Chemistry Program, 2012-13.
3. Graduate Track Awards: Academic Excellence, 2013-14.
4. NIH Training Grant Research Fellowship-Biological Chemistry Program, 2013-14.

Publications
1. Gunawan S., Ayaz M., De Moliner F., Frett, B., Kaiser C., Patrick N., Xu Z., Hulme C. Synthesis of tetrazolo-fused benzodiazepines and benzodiazepinones by a two-step protocol using an Ugi-Azide reaction for initial diversity generation. Tetrahedron (2012), 68, 5606-5611.
2. Roberts S., Saha B., Frett, B., Li H., Title (Z)-N-(tert-butyl)-N’-(4-methoxyphenyl)-2-((4-methoxyphenyl)amino)-2-phenyl¬ acetimidamide, Acta Cryst E (2013), E69, o902.
3. Saha, B., Frett, B., Wang, Y., Li, H., A p-toluenesulfinic acid-catalyzed three-component Ugi-type reaction and its application for the synthesis of α-amino amides and amidines. Tetrahedron Letters (2013), 54, 2340-2343.
4. Wang, Y., Kaiser C., Frett, B., Li, H., Targeting mutant KRAS for anticancer therapeutics: a review of novel small molecule modulators. J Med Chem (2013), 56, 5219-5230.
5. Frett, B.; Wang, Y.; Li, H. Targeting the K-Ras/PDEδ Protein–Protein Interaction: The Solution for Ras-Driven Cancers or Just Another Therapeutic Mirage? Chem Med Chem (2013), 8, 1620-1622.
6. Wang, Y.; Saha, B.; Li, F.; Frett, B.; Li, H. An expeditious approach to access 2-arylimidazo[1,2-a]pyridin-3-ol from 2-amino pyridine through a novel Petasis based cascade reaction. Tetrahedron Letters (2014) 55, 1281-1284.
7. Frett, B.; Brown, RV; Ma, M; Hu, W.; Han, H.; Li, H. The Therapeutic Melting Pot of Never in Mitosis Gene A-Related Kinase 2 (Nek2): A Perspective on Nek2 as an Oncology Target and Recent Advancements in Nek2 Small Molecule Inhibition. J Med Chem (2014), 57, 5835-5844.
8. Wang, Y.; Frett, B.; Li, H. Efficient Access to 2,3-Diarylimidazo[1,2-a]pyridines via a One-Pot, Ligand-Free, Palladium-Catalyzed Three-Component Reaction under Microwave Irradiation. Organic Letters (2014), 16, 3016-3019.
9. Fang, Li; Frett, B.; Li, H. Selective Reduction of Halogenated Nitroarenes with Hydrazine Hydrate in the Presence of Pd/C. SynLett (2014), 25, 1403-1408.
10. Frett, B.; McConnell, N.;Wang, Y.; Xu, Z.; Ambrose, A.; Li, H. Identification of pyrazine-based TrkA inhibitors: design, synthesis, evaluation, and computational modelling studies. MedChemComm (2014)
11. Frett, B.; Moccia, M.; Carlomango, F.; Santoro, M.; Li, H. Identification of two novel RET kinase inhibitors through MCR-based drug discovery: design, synthesis and evaluation. Eur J Med Chem (2014), 86, 714-723.
12. Wang. Y.; Frett, B.; McConnell, N.; Li, H. Metal-Free, Efficient Hydrazination of Imidazo[1,2-a]pyridine with Diethyl Azodicarboxylate in Neutral Media. Organic & Bimolecular Chemistry (2015), 13, 2958-2964.
13. McConnell, N.; Frett, B.; Li, H. Microwave Assisted Green Synthesis of Anilines and Phenols without Transition Metals, Ligands, or Organic Solvents. Green Chemistry (2015) (submitted).
14. Frett, B.; Carlomagno, F.; Moccia, L; Brescia, A.; Federico, G.; De Falco, V.; Admire, B.; Chen, Z.; Qi, W.; Massimo, S.; Li, H. Fragment-based discovery of a dual pan-RET/VEGFR2 kinase inhibitor optimized for single-agent polypharmacology. Angewandte Chemie (2015) (Accepted with minor revisions).
15. Frett, B.; McConnell, N.; Smith, C.; Shah, N.P.; Li, H. Computer Aided Drug Discovery of Highly Ligand Efficient, Low Molecular Weight Imidazopyridine Analogues as FLT3 Inhibitors. Eur J Med Chem (2015), 94, 123-131.
Originally posted: October 24, 2014
Last updated: December 19, 2016
Want to update? Contact Webmaster
Share This